Tuesday, November 8 -- The Italian Prime Minister Matteo Renzi, has today visited Chiesi Farmaceutici at the Research Center in Parma. The Prime Minister scheduled a meeting with Ugo di Francesco, Group CEO, Paolo Chiesi, Vice President, Alessandro Chiesi, Region Europe Director and Andrea Chiesi, R&D Portfolio Management and members of the Executive Committee. He was then accompanied to a tour of our research labs.
"It is an honour, for us and for our Company, to host the Premier Renzi at our headquarters in Parma, which is the heart of R&D and production of the Group and the headquarter of Chiesi Farmaceutici," commented Ugo Di Francesco, "the interest he showed for our Company, as an important multinational Italian reality, is a matter of great satisfaction for all of us”
About Chiesi Farmaceutici
Headquartered in Parma, Italy Chiesi Farmaceutici is an international research-focused Healthcare group. Chiesi researches, develops and markets innovative drugs in the respiratory therapeutics, neonatology specialist medicine and rare diseases areas.
In 2015 Chiesi Farmaceutici achieved an annual turnover of over 1.46 billion euros, increasing of 9.4% compared 2014
Its R&D centres in Parma (Italy), Paris (France), Cary (USA), Chippenham (UK) and the R&D team of the subsidiary Danish company Zymenex (Sweden and Denmark) , integrate their efforts to advance Chiesi's pre-clinical, clinical and registration programs. Chiesi employs over 4,500 people, 560 of whom are solely dedicated to Research and Development activities.
# # #
Contatti:
Valentina Biagini
Group Communication Manager
telefono +39 348 7693 623
email v.biagini@chiesi.com
